Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2007 1
2008 2
2009 1
2010 3
2013 1
2015 2
2016 2
2017 10
2018 8
2019 2
2020 1
2021 1
2022 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean m ghajarzadeh (44 results)?
Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
Behfar M, Koochakzadeh L, Yazdanian N, Salajegheh P, Rostami T, Khodayari-Namini N, Ghavamzadeh A, Hamidieh AA. Behfar M, et al. Turk J Pediatr. 2019;61(3):407-412. doi: 10.24953/turkjped.2019.03.013. Turk J Pediatr. 2019. PMID: 31916719 Free article.
Behfar M, Koochakzadeh L, Yazdanian N, Salajegheh P, Rostami T, Khodayari-Namini N, Ghavamzadeh A, Hamidieh AA. ...
Behfar M, Koochakzadeh L, Yazdanian N, Salajegheh P, Rostami T, Khodayari-Namini N, Ghavamzadeh A, Hamidieh AA. ...
Comparison of 60 and 80 mg/m(2) of daunorubicin in induction therapy of acute myeloid leukaemia.
Vaezi M, Bahar B, Mousavi A, Yaghmai M, Kasaeian A, Souri M, Jahani M, Alimoghaddam K, Ghavamzadeh A. Vaezi M, et al. Hematol Oncol. 2017 Mar;35(1):101-105. doi: 10.1002/hon.2236. Epub 2015 Aug 3. Hematol Oncol. 2017. PMID: 26386260 Clinical Trial.
Total of 114 patients were included in the study. Fifty-five patients received 60 mg/m(2) of daunorubicin (arm 1) 1 h IV infusion for 3 days, and the remaining 59 received 80 mg/m(2) (arm 2) 1 h IV infusion for 3 days. ...Considering these results, we found that 60 …
Total of 114 patients were included in the study. Fifty-five patients received 60 mg/m(2) of daunorubicin (arm 1) 1 h IV infusion for …
Medical oncology, history and its future in Iran.
Mirzania M, Ghavamzadeh A, Asvadi Kermani I, Ashrafi F, Allahyari A, Rostami N, Razavi SM, Ramzi M, Nemanipour G. Mirzania M, et al. Arch Iran Med. 2015 Nov;18(11):799-805. Arch Iran Med. 2015. PMID: 26497380
The relationship of dietary total antioxidant capacity with sarcopenia and cardiometabolic biomarkers in type 2 diabetes patients.
Baharirad N, Pasdar Y, Nachvak M, Ghavamzadeh S, Soroush A, Saber A, Mostafai S, Naghipour A, Abdollahzad H. Baharirad N, et al. Physiol Rep. 2022 Feb;10(3):e15190. doi: 10.14814/phy2.15190. Physiol Rep. 2022. PMID: 35150209 Free PMC article.
RESULTS: The mean age and body mass index were 49.7 8.7 years and 27.1 3.9 kg/m(2) . Body mass index, waist circumference, and hip circumference were significantly different between diabetic patients with and without sarcopenia (p < 0.05). ...
RESULTS: The mean age and body mass index were 49.7 8.7 years and 27.1 3.9 kg/m(2) . Body mass index, waist circumference, and hip ci …
A Comparison of Dexamethasone Plus Vincristine versus Standard Regimen in Induction Therapy of Adult Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplantation.
Vaezi M, Pourkhani A, Kasaeian A, Souri M, Yaghmaie M, Chardouli B, Alimoghaddam K, Ghavamzadeh A. Vaezi M, et al. Int J Hematol Oncol Stem Cell Res. 2022 Jan 1;16(1):22-33. doi: 10.18502/ijhoscr.v16i1.8439. Int J Hematol Oncol Stem Cell Res. 2022. PMID: 35975121 Free PMC article.
Materials and Methods: To lessen induction regimen complications in ALL patients who undergo HSCT, we used a cytoreduction induction regimen including dexamethasone (8 mg, IV, three times a day, for 28 days) and vincristine(1.4 mg/m(2), IV, on days 1,8,15 and 22) for 49 ne …
Materials and Methods: To lessen induction regimen complications in ALL patients who undergo HSCT, we used a cytoreduction induction regimen …
Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest.
Hassani S, Ghaffari SH, Zaker F, Mirzaee R, Mardani H, Bashash D, Zekri A, Yousefi M, Zaghal A, Alimoghaddam K, Ghavamzadeh A. Hassani S, et al. Ann Hematol. 2013 Sep;92(9):1207-20. doi: 10.1007/s00277-013-1763-8. Epub 2013 May 5. Ann Hematol. 2013. PMID: 23645216
Cell cycle distribution, ROS level, and caspase-3 activation analyses suggest that AZT reduced the ATO-induced cytotoxic effect possibly via relative induction and diminution of cells accumulated in (G1, S) and (G2/M) phase, respectively, as well as through attenuation of …
Cell cycle distribution, ROS level, and caspase-3 activation analyses suggest that AZT reduced the ATO-induced cytotoxic effect possibly via …
Evaluation of nutritional status in patients undergoing hematopoietic SCT.
Hadjibabaie M, Iravani M, Taghizadeh M, Ataie-Jafari A, Shamshiri AR, Mousavi SA, Alimoghaddam K, Hosseini S, Ghavamzadeh A. Hadjibabaie M, et al. Bone Marrow Transplant. 2008 Oct;42(7):469-73. doi: 10.1038/bmt.2008.188. Epub 2008 Jul 7. Bone Marrow Transplant. 2008. PMID: 18604243
Patients (14%) were underweight (BMI<18.5 kg/m(2)), 58% in a normal BMI (between 18.5 and 24.9 kg/m(2)) and 28% were overweight or obese (BMI >or= 25 kg/m(2)). ...
Patients (14%) were underweight (BMI<18.5 kg/m(2)), 58% in a normal BMI (between 18.5 and 24.9 kg/m(2)) and 28% were overwe …
Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.
Momeny M, Sabourinejad Z, Zarrinrad G, Moghaddaskho F, Eyvani H, Yousefi H, Mirshahvaladi S, Poursani EM, Barghi F, Poursheikhani A, Dardaei L, Bashash D, Ghazi-Khansari M, Tavangar SM, Dehpour AR, Yaghmaie M, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Momeny M, et al. Sci Rep. 2017 Apr 6;7:45954. doi: 10.1038/srep45954. Sci Rep. 2017. PMID: 28383032 Free PMC article.
Tivozanib, a pan-inhibitor of VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell cycle arrest and apoptotic cell death. Tivozanib decreased invasive potential of these cells, concomitant with reduction of intercellular adhe …
Tivozanib, a pan-inhibitor of VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell cy …
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.
Momeny M, Moghaddaskho F, Gortany NK, Yousefi H, Sabourinejad Z, Zarrinrad G, Mirshahvaladi S, Eyvani H, Barghi F, Ahmadinia L, Ghazi-Khansari M, Dehpour AR, Amanpour S, Tavangar SM, Dardaei L, Emami AH, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Momeny M, et al. Sci Rep. 2017 Mar 13;7:44075. doi: 10.1038/srep44075. Sci Rep. 2017. PMID: 28287096 Free PMC article.
Here we show that tivozanib, a pan-inhibitor of vascular endothelial growth factor (VEGF) receptors, inhibited proliferation of GBM cells through a G2/M cell cycle arrest via inhibition of polo-like kinase 1 (PLK1) signalling pathway and down-modulation of Aurora kinases A …
Here we show that tivozanib, a pan-inhibitor of vascular endothelial growth factor (VEGF) receptors, inhibited proliferation of GBM cells th …
32 results